Lineage Cell Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lineage Cell Therapeutics, Inc.
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.
The US biotech’s TSHA-102 has shown surprisingly early signs of functional improvement in a single patient treated in its Phase I/II Rett syndrome trial, promoting a major stock surge supported by the news of a $150 private placement and regulatory updates.
Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.
News We’re Watching: Quidel Recall, Partnerships For Teladoc And Lifebit, Alaris Cybersecurity Issues
This week, Quidel recalled the Triage cardiac panel due to a risk of false results; Teladoc and Lifebit announced new partnerships; and, a court upheld a false advertising verdict against Natera, but struck the financial penalties.
- Drug Delivery
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Asterias Biotherapeutics, Inc.
- BioTime Acquisition Corp.
- BioTime, Inc.
- Cell Cure Neurosciences Ltd.
- Embryome Sciences
- ES Cell International Pte Ltd
- LifeMap Sciences, Inc.
- OncoCyte Corporation
- ReCyte Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.